# A Study of Paliperidone Palmitate 6-Month Formulation

> **NCT03345342** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 841 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** PP6M
- **DRUG:** PP3M 350 mg eq.
- **DRUG:** PP3M 525 mg eq.
- **DRUG:** PP1M
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03345342
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-20
- **Primary completion:** 2020-05-08
- **Final completion:** 2020-05-08
- **Target enrollment:** 841 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03345342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03345342, "A Study of Paliperidone Palmitate 6-Month Formulation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03345342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*